Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioasis Technologies Inc. (BIOAF)
New Haven, CT, US
Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and disease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -50.00% | -50.00% | -50.00% | -50.00% | +0.00% | -99.09% | -99.95% | -99.99% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-99.1% Q4'22: +294.8% (vs Q4'21)
-
EPS growth Biotechnology: +29.7%-498.1% Q4'22: +28.4% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%-12,187.6% Q4'22: -297.6% (vs Q4'21)
-
EBIT margin Biotechnology: +0.0%-9,534.2% Q4'22: -519.4% (vs Q4'21)
-
ROIC Biotechnology: -16.1%— Q4'22: +483.5% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+6.0% Q4'22: +8.4% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.54× Q4'22: -0.83× (vs Q4'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Feb 2015 actual |
Feb 2016 actual |
Feb 2018 actual |
Feb 2019 actual |
Feb 2020 actual |
Feb 2021 actual |
Feb 2022 actual |
Feb 2023 actual |
Feb 2024 actual |
Feb 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 10.51M (-100.0%)
|
369.1K
est: 24.68M (-98.5%)
|
589.8K
est: 10.81M (-94.5%)
|
1.42M
est: 24.38M (-94.2%)
|
606.4K
est: 605.8K (+0.1%)
|
4.08M
est: 5.54M (-26.4%)
|
37.7K
est: 38.1K (-1.0%)
|
99.6K
est.
|
46.4K
est.
|
51.4K
est.
|
| EBITDA |
-2.79M
est: -8.18M (+65.9%)
|
-2.51M
est: -19.21M (+86.9%)
|
-5.22M
est: -8.41M (+38.0%)
|
-4.79M
est: -18.98M (+74.8%)
|
-4.54M
est: -471.6K (-861.7%)
|
438.2K
est: -4.31M (+110.2%)
|
-3.54M
est: -29.7K (-11,840.7%)
|
-77.6K
est.
|
-36.1K
est.
|
-40.0K
est.
|
| EBIT |
-2.84M
est: -8.21M (+65.4%)
|
-2.56M
est: -19.28M (+86.7%)
|
-5.28M
est: -8.45M (+37.5%)
|
-4.86M
est: -19.05M (+74.5%)
|
-4.60M
est: -473.4K (-872.1%)
|
380.1K
est: -4.33M (+108.8%)
|
-3.60M
est: -29.8K (-11,981.5%)
|
-77.9K
est.
|
-36.2K
est.
|
-40.2K
est.
|
| Net Income |
-2.84M
est: 5.78M (-149.1%)
|
-2.57M
est: 14.96M (-117.2%)
|
-5.31M
est: 5.94M (-189.3%)
|
-3.47M
est: 14.78M (-123.5%)
|
-4.06M
est: -3.59M (-13.0%)
|
698.4K
est: 2.52M (-72.2%)
|
-2.96M
est: -4.34M (+31.8%)
|
-2.88M
est.
|
-5.05M
est.
|
-5.04M
est.
|
| SGA |
1.49M
est: 168.65M (-99.1%)
|
1.67M
est: 396.10M (-99.6%)
|
4.45M
est: 173.50M (-97.4%)
|
4.31M
est: 391.34M (-98.9%)
|
3.17M
est: 9.72M (-67.4%)
|
2.46M
est: 88.90M (-97.2%)
|
2.41M
est: 611.6K (+293.8%)
|
1.60M
est.
|
744.7K
est.
|
825.8K
est.
|
| EPS |
-0.07
est: 0.08 (-182.4%)
|
-0.06
est: 0.21 (-127.9%)
|
-0.10
est: 0.08 (-221.4%)
|
-0.06
est: 0.20 (-129.9%)
|
-0.07
est: -0.05 (-30.9%)
|
0.01
est: 0.03 (-70.5%)
|
-0.04
est: -0.06 (+31.9%)
|
-0.04
est.
|
-0.07
est.
|
-0.07
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Deborah Ann Rathjen FTSE | Chief Executive Officer & President | 152.6K | — |
| David Jenkins | Chief Financial Officer | 91.5K | male |
| Aaron Elton | Director of Marketing | — | male |
| Graeme Dick | Director of Investor Relations | — | male |
| Mei Mei Tian | Vice President & Head of External Research | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BIOAF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
